Overview

Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Head and Neck Cancer

Status:
Completed
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to provide access to paclitaxel therapy to subjects with advanced head and neck cancer who have completed the previous late phase 2 study (CA139-388) and should have continued therapy with paclitaxel as the discretion of the investigator, and to evaluate the frequency and the severity of observed adverse reactions in treated subjects
Phase:
Phase 2
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Albumin-Bound Paclitaxel
Paclitaxel